Position paper on CDK4/6 inhibitors in early breast cancer

被引：1

作者：

Gnant, Michael ^{[1
]}

Singer, Christian F. ^{[2
]}

Rinnerthaler, Gabriel ^{[3
]}

Pfeiler, Georg ^{[2
]}

Egle, Daniel ^{[4
]}

Balic, Marija ^{[5
]}

Bartsch, Rupert ^{[6
]}

机构：

[1] Med Univ Vienna, Comprehens Canc Ctr, Vienna, Austria

[2] Med Univ Vienna, Dept Gynecol & Gynecol Oncol, Vienna, Austria

[3] Paracelsus Med Univ Salzburg, Oncol Ctr, Dept Internal Med 3, Haematol Med Oncol Haemostaseol Infectiol & Rheuma, A-5020 Salzburg, Austria

[4] Med Univ Innsbruck, Breast Canc Ctr Tirol, Dept Gynecol, Innsbruck, Austria

[5] Med Univ Graz, Dept Internal Med, Div Clin Oncol, Graz, Austria

[6] Med Univ Vienna, Dept Med 1, Div Oncol, Vienna, Austria

来源：

MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY | 2023年 / 16卷 / 02期

关键词：

Breast cancer; Adjuvant therapy; Cell cycle inhibitors; CDK4; 6; inhibitors; RIBOCICLIB PLUS LETROZOLE; THYMIDINE KINASE-ACTIVITY; ENDOCRINE THERAPY; NEOADJUVANT PALBOCICLIB; MOLECULAR PORTRAITS; INTRINSIC SUBTYPES; OPEN-LABEL; MULTICENTER; RESISTANCE; SIGNATURE;

D O I：

10.1007/s12254-023-00878-1

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Inhibitors of the cyclin-dependent kinases 4/6 (CDK4/6i) have been practice-changing and are now considered the standard of care in combination with endocrine therapy for the first- or second-line treatment in advanced hormone-receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. Recently, CDK4/6i have also emerged as an appealing targeted cancer therapy in early breast cancer, however results of large clinical trials are controversial. This position paper summarizes the evidence, and provides guidance for clinical practice.

引用

页码：135 / 144

页数：10

共 50 条

[21] Targeting CDK4/6 in breast cancer
Shanabag, Anusha
Armand, Jessica
Son, Eugene
Yang, Hee Won
EXPERIMENTAL AND MOLECULAR MEDICINE, 2025, 57 (02) : 312 - 322
[22] CDK4/6 inhibitors as adjuvant therapy in early breast cancer? Uncertain benefits, guaranteed harms
Haslam, Alyson
Ranganathan, Sruthi
Prasad, Vinay
Olivier, Timothee
EUROPEAN JOURNAL OF CANCER, 2024, 207
[23] First clinical experience with CDK4/6 inhibitors in breast cancer therapy
Cobec, Ionut Marcel
Moleriu, Lavinia
Moatar, Aurica Elisabeta
Rempen, Andreas
EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2021, 21 (05)
[24] Recent advances of highly selective CDK4/6 inhibitors in breast cancer
Xu, Hanxiao
Yu, Shengnan
Liu, Qian
Yuan, Xun
Mani, Sridhar
Pestell, Richard G.
Wu, Kongming
JOURNAL OF HEMATOLOGY & ONCOLOGY, 2017, 10
[25] CDK4/6 inhibitors in HR-positive breast cancer immunotherapy
Shen, Mimi
Ma, Zhiyuan
Zhu, Jiaxing
Wen, Guorong
Jin, Hai
An, Jiaxing
Tuo, Biguang
Liu, Xuemei
Li, Taolang
BIOORGANIC CHEMISTRY, 2025, 154
[26] CDK4/6 Inhibitors : Promising Opportunities beyond Breast Cancer
Lim, Joline S. J.
Turner, Nicholas C.
Yap, Timothy A.
CANCER DISCOVERY, 2016, 6 (07) : 697 - 699
[27] Clinical and Pharmacologic Differences of CDK4/6 Inhibitors in Breast Cancer
George, Mridula A.
Qureshi, Sadaf
Omene, Coral
Toppmeyer, Deborah L.
Ganesan, Shridar
FRONTIERS IN ONCOLOGY, 2021, 11
[28] An Update on the Clinical Use of CDK4/6 Inhibitors in Breast Cancer
Robert, Marie
Frenel, Jean-Sebastien
Bourbouloux, Emmanuelle
Rigaud, Dominique Berton
Patsouris, Anne
Augereau, Paule
Gourmelon, Carole
Campone, Mario
DRUGS, 2018, 78 (13) : 1353 - 1362
[29] Real-World Analysis of Breast Cancer Patients Qualifying for Adjuvant CDK4/6 Inhibitors
Kanjanapan, Yada
Anderson, Wayne
Smith, Mirka
Green, Jenny
Chalker, Elizabeth
Craft, Paul
CLINICAL BREAST CANCER, 2025, 25 (02) : e159 - e169.e2
[30] Potential biomarkers of CDK4/6 inhibitors in hormone receptor-positive advanced breast cancer
Fang, Hehui
Huang, Doudou
Yang, Fang
Guan, Xiaoxiang
BREAST CANCER RESEARCH AND TREATMENT, 2018, 168 (02) : CP8 - 297

← 1 2 3 4 5 →